These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

193 related items for PubMed ID: 23784628

  • 21. Investigation of the biophysical and cell biological properties of ferroportin, a multipass integral membrane protein iron exporter.
    Rice AE, Mendez MJ, Hokanson CA, Rees DC, Björkman PJ.
    J Mol Biol; 2009 Feb 27; 386(3):717-32. PubMed ID: 19150361
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. In vitro functional analysis of human ferroportin (FPN) and hemochromatosis-associated FPN mutations.
    Schimanski LM, Drakesmith H, Merryweather-Clarke AT, Viprakasit V, Edwards JP, Sweetland E, Bastin JM, Cowley D, Chinthammitr Y, Robson KJ, Townsend AR.
    Blood; 2005 May 15; 105(10):4096-102. PubMed ID: 15692071
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Alternative splicing generates a novel ferroportin isoform with a shorter C-terminal and an intact iron- and hepcidin-binding property.
    Juneja P, Rashid N, Abul Qais F, Tanwar S, Sultan I, Ahmad F, Rehman SU.
    IUBMB Life; 2024 Aug 15; 76(8):523-533. PubMed ID: 38348962
    [Abstract] [Full Text] [Related]

  • 26. A novel mutation in the SLC40A1 gene associated with reduced iron export in vitro.
    Moreno-Carralero MI, Muñoz-Muñoz JA, Cuadrado-Grande N, López-Rodríguez R, José Hernández-Alfaro M, del-Castillo-Rueda A, Enríquez-de-Salamanca R, Méndez M, Morán-Jiménez MJ.
    Am J Hematol; 2014 Jul 15; 89(7):689-94. PubMed ID: 24644245
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Functional characterization of fluorescent hepcidin.
    Dürrenberger F, Abbate V, Ma Y, Arno MC, Jaiash D, Parmar A, Marshall V, Latunde-Dada GO, Zimmermann T, Senn D, Altermatt P, Manolova V, Hider RC, Bansal SS.
    Bioconjug Chem; 2013 Sep 18; 24(9):1527-32. PubMed ID: 23888876
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Update on iron metabolism and molecular perspective of common genetic and acquired disorder, hemochromatosis.
    Yun S, Vincelette ND.
    Crit Rev Oncol Hematol; 2015 Jul 18; 95(1):12-25. PubMed ID: 25737209
    [Abstract] [Full Text] [Related]

  • 31. Biology of the iron efflux transporter, ferroportin.
    Rishi G, Subramaniam VN.
    Adv Protein Chem Struct Biol; 2021 Jul 18; 123():1-16. PubMed ID: 33485480
    [Abstract] [Full Text] [Related]

  • 32. Outward- and inward-facing structures of a putative bacterial transition-metal transporter with homology to ferroportin.
    Taniguchi R, Kato HE, Font J, Deshpande CN, Wada M, Ito K, Ishitani R, Jormakka M, Nureki O.
    Nat Commun; 2015 Oct 13; 6():8545. PubMed ID: 26461048
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Structural basis of ion transport and inhibition in ferroportin.
    Pan Y, Ren Z, Gao S, Shen J, Wang L, Xu Z, Yu Y, Bachina P, Zhang H, Fan X, Laganowsky A, Yan N, Zhou M.
    Nat Commun; 2020 Nov 10; 11(1):5686. PubMed ID: 33173040
    [Abstract] [Full Text] [Related]

  • 35. Structure of hepcidin-bound ferroportin reveals iron homeostatic mechanisms.
    Billesbølle CB, Azumaya CM, Kretsch RC, Powers AS, Gonen S, Schneider S, Arvedson T, Dror RO, Cheng Y, Manglik A.
    Nature; 2020 Oct 10; 586(7831):807-811. PubMed ID: 32814342
    [Abstract] [Full Text] [Related]

  • 36. Analysis of SLC40A1 gene at the mRNA level reveals rapidly the causative mutations in patients with hereditary hemochromatosis type IV.
    Speletas M, Kioumi A, Loules G, Hytiroglou P, Tsitouridis J, Christakis J, Germenis AE.
    Blood Cells Mol Dis; 2008 Oct 10; 40(3):353-9. PubMed ID: 17997113
    [Abstract] [Full Text] [Related]

  • 37. Reduced iron export associated with hepcidin resistance can explain the iron overload spectrum in ferroportin disease.
    Viveiros A, Panzer M, Baumgartner N, Schaefer B, Finkenstedt A, Henninger B, Theurl I, Nachbaur K, Weiss G, Haubner R, Decristoforo C, Tilg H, Zoller H.
    Liver Int; 2020 Aug 10; 40(8):1941-1951. PubMed ID: 32450003
    [Abstract] [Full Text] [Related]

  • 38. The molecular basis of ferroportin-linked hemochromatosis.
    De Domenico I, Ward DM, Nemeth E, Vaughn MB, Musci G, Ganz T, Kaplan J.
    Proc Natl Acad Sci U S A; 2005 Jun 21; 102(25):8955-60. PubMed ID: 15956209
    [Abstract] [Full Text] [Related]

  • 39. Ferroportin disease: a systematic meta-analysis of clinical and molecular findings.
    Mayr R, Janecke AR, Schranz M, Griffiths WJ, Vogel W, Pietrangelo A, Zoller H.
    J Hepatol; 2010 Nov 21; 53(5):941-9. PubMed ID: 20691492
    [Abstract] [Full Text] [Related]

  • 40. Ironing out Ferroportin.
    Drakesmith H, Nemeth E, Ganz T.
    Cell Metab; 2015 Nov 03; 22(5):777-87. PubMed ID: 26437604
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.